Primecap Management Co. CA Reduces Holdings in BioNTech SE Sponsored ADR $BNTX

Primecap Management Co. CA trimmed its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 1.1% in the second quarter, Holdings Channel.com reports. The institutional investor owned 4,001,466 shares of the company’s stock after selling 44,959 shares during the quarter. Primecap Management Co. CA’s holdings in BioNTech were worth $426,036,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. BNP Paribas Financial Markets raised its position in BioNTech by 94.6% in the first quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company’s stock worth $108,859,000 after acquiring an additional 581,173 shares in the last quarter. Bank of New York Mellon Corp increased its stake in BioNTech by 58.8% in the second quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after purchasing an additional 410,351 shares during the last quarter. Aberdeen Group plc raised its stake in shares of BioNTech by 87.2% in the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock valued at $76,864,000 after acquiring an additional 336,260 shares during the period. Invesco Ltd. boosted its position in BioNTech by 643.7% during the 1st quarter. Invesco Ltd. now owns 645,142 shares of the company’s stock worth $58,747,000 after purchasing an additional 558,389 shares during the period. Finally, Millennium Management LLC raised its stake in shares of BioNTech by 252.5% during the first quarter. Millennium Management LLC now owns 544,970 shares of the company’s stock valued at $49,625,000 after purchasing an additional 390,360 shares during the period. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Down 0.1%

NASDAQ:BNTX opened at $102.53 on Wednesday. The firm has a market capitalization of $24.65 billion, a price-to-earnings ratio of -64.08 and a beta of 1.54. The company has a current ratio of 8.61, a quick ratio of 8.48 and a debt-to-equity ratio of 0.01. The business’s fifty day moving average price is $102.92 and its 200 day moving average price is $104.94. BioNTech SE Sponsored ADR has a 1-year low of $81.20 and a 1-year high of $129.27.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.75 by ($0.89). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The firm had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same period in the previous year, the business posted $0.81 EPS. BioNTech’s revenue for the quarter was up 22.0% on a year-over-year basis. BioNTech has set its FY 2025 guidance at EPS. On average, sell-side analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current fiscal year.

Analyst Ratings Changes

BNTX has been the topic of several analyst reports. Berenberg Bank restated a “buy” rating on shares of BioNTech in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of BioNTech in a research note on Tuesday, October 14th. Morgan Stanley reissued an “overweight” rating and set a $134.00 target price on shares of BioNTech in a report on Monday, November 3rd. Jefferies Financial Group reaffirmed a “buy” rating on shares of BioNTech in a report on Wednesday, November 12th. Finally, Cowen reiterated a “hold” rating on shares of BioNTech in a research report on Monday, November 3rd. Ten research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $135.20.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.